On Tuesday, the FDA granted Philip Morris the ability to market 20 Zyn nicotine pouch products with a modified-risk claim, stating that switching from cigarettes to Zyn can lower the risk of several serious health issues, including mouth cancer and heart disease.
This decision aligns with the Trump administration's recent trend of loosening restrictions on nicotine products, reflecting a more industry-friendly approach. Zyn pouches, which contain nicotine but no tobacco, have gained popularity among various demographics, particularly conservatives and tech workers, as a perceived cleaner alternative to smoking.
Despite the FDA's acknowledgment that no tobacco product is safe, this ruling allows Philip Morris to leverage a health-related marketing angle for one of the fastest-growing segments in the nicotine market, especially as cigarette sales decline. The approval follows significant lobbying from the tobacco industry advocating for more access to less harmful alternatives.
Notably, Zyn has also become intertwined with conservative culture, with figures like Tucker Carlson promoting the brand. The FDA had previously authorized these products for sale but did not permit health claims until now, marking a pivotal moment for Philip Morris as it continues to invest in smoke-free products amid changing regulatory landscapes